Crossing the fourth hurdle
نویسندگان
چکیده
منابع مشابه
Issues for countries considering introducing the "fourth hurdle": the case of Hungary.
OBJECTIVES This study outlines the needs and current development of the "fourth hurdle" (i.e., requirement of effectiveness and cost-effectiveness data for drug coverage policy decisions) in Hungary, describes the legal background and seeks to address some of the most important questions in this field. METHODS The study draws on international experiences and discusses five issues that a given...
متن کاملInclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle.
http://bmj.com/cgi/content/full/329/7472/972 Updated information and services can be found at: These include: Data supplement http://bmj.com/cgi/content/full/329/7472/972/DC1 prices" "References w1 w16, further details and figures showing the effect on drug References http://bmj.com/cgi/content/full/329/7472/972#otherarticles 1 online articles that cite this article can be accessed at: http://b...
متن کاملThe hurdle-race problem
We consider the problem of how to determine the required level of the current provision in order to be able to meet a series of future deterministic payment obligations, in case the provision is invested according to a given random return process. Approximate solutions are derived, taking into account imposed minimum levels of the future random values of the reserve. The paper ends with numeric...
متن کاملClearing up the hazy road from bench to bedside: A framework for integrating the fourth hurdle into translational medicine
BACKGROUND New products evolving from research and development can only be translated to medical practice on a large scale if they are reimbursed by third-party payers. Yet the decision processes regarding reimbursement are highly complex and internationally heterogeneous. This study develops a process-oriented framework for monitoring these so-called fourth hurdle procedures in the context of ...
متن کاملDFM: The Real 90nm Hurdle
Design for Manufacturability (DFM) has always been important, but is vital as we move to 90nm technologies. The line between defects and process variation has blurred to the point that in some cases it is no longer meaningful. This means that yield and quality level are becoming more design dependent than ever, and that test effectiveness cannot be guaranteed without strict DFM guidelines. With...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Clinical Pharmacology
سال: 2012
ISSN: 0306-5251
DOI: 10.1111/j.1365-2125.2012.04263.x